SPONSOR
New York Medical College
Total Trials
6
Recruiting
6
Phases
Phase 2, Phase 1, Phase 3, EARLY_Phase 1, Phase 1, Phase 2
Conditions studied: Non-Hodgkin LymphomaBurkitt LymphomaDiffuse Large B-Cell LymphomaPrimary Mediastinal B-cell LymphomaCD20+ Lymphoblastic LymphomaFollicular Lymphoma, Grade IIICytomegalovirus InfectionsPrimary Immune Deficiency DisorderImmune Thrombocytopenic PurpuraCMV
New York Medical College is a clinical research sponsor with 6 registered studies on ClinicalTrials.gov, of which 6 are actively recruiting participants. Research covers conditions including Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Primary Mediastinal B-cell Lymphoma.
The trial portfolio spans Phase 2, Phase 1, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — New York Medical College
How many clinical trials has New York Medical College sponsored?
ClinicalMetric currently tracks 6 clinical trials sponsored by New York Medical College, of which 6 are actively recruiting participants. These trials cover conditions including Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does New York Medical College research focus on?
New York Medical College clinical trials span Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Primary Mediastinal B-cell Lymphoma, CD20+ Lymphoblastic Lymphoma, and additional conditions. The research pipeline includes Phase 2, Phase 1, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a New York Medical College clinical trial?
To participate in a New York Medical College trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all New York Medical College trials with current recruitment status updated daily.
Clinical Trials by New York Medical College
NCT02393157 Phase 2
Recruiting
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
Non-Hodgkin Lymphoma
NCT03266640 Phase 2
Recruiting
Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
Cytomegalovirus Infections
NCT04323748 Phase 1
Recruiting
Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura
Immune Thrombocytopenic Purpura
NCT07225972 Phase 3
Recruiting
Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC Alone
CMV
NCT03719105 EARLY_Phase 1
Recruiting
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
NK-Cell Lymphoma
NCT04896606 Phase 1, Phase 2
Recruiting
SARS-CoV-2 CTLS for Mild to Moderate COVID-19 Disease
Covid19
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology